Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index; 70 of the 140 sources its claims cite were checked for support.

Nitazenes: The Emergence of a Potent Synthetic Opioid Threat

Open access

Abstract

The global unregulated drug supply faces a critical challenge with the emergence of nitazenes, a class of novel synthetic opioids (NSOs) structurally distinct from fentanyl and associated with extreme potency and high risk of fatal overdose. First synthesised in the late 1950s, etonitazene was a target of preclinical research in rats and rhesus monkeys, but it never reached clinical trials due to an unfavourable balance between therapeutic and toxic effects. Nitazenes' consistent reappearance began in 2019 with isotonitazene, followed by a rapid proliferation of analogues worldwide, many reported to be hundreds to thousands of times more potent than morphine and, in some cases, stronger than fentanyl. This rise is fuelled by their ease of synthesis, low production costs, and evasion of regulatory controls. Nitazenes are frequently mis-sold as counterfeit medications or adulterated into other drugs, resulting in unintentional exposure and overdose, particularly among opioid-naïve users. The primary cause of death is severe and prolonged respiratory depression. Analytical challenges are significant, as traditional screening methods are ineffective, and the low concentration in biological samples requires expensive and highly sensitive liquid chromatography mass spectrometry techniques. This perspective paper highlights critical gaps in detection, clinical management, and regulatory readiness for nitazenes. Urgent efforts are needed to improve surveillance, develop robust analytical methodologies, provide clinical guidance to nitazene intoxications, and strengthen international policy to curb their proliferation.

Overview

CoChat Summary

TL;DR

This perspective paper reviews the emergence of nitazenes, a class of highly potent 2-benzylbenzimidazole synthetic opioids distinct from fentanyl, and argues they pose an escalating global overdose threat. It highlights critical gaps in detection, clinical management, and regulatory readiness, calling for improved surveillance, analytical methods, naloxone guidance, and international control.

Key findings

  • Nitazenes were first synthesised in the late 1950s but never approved clinically; isotonitazene emerged in 2019, followed by dozens of analogues, with 12 nitazenes scheduled by the UN Commission on Narcotic Drugs and around 30 reported through the UNODC Early Warning Advisory System.
  • Potency varies widely: etonitazene is reported as 100–1000 times more potent than morphine and 10–20 times more potent than fentanyl; isotonitazene ~500 times morphine; metonitazene equipotent to fentanyl and ~100 times morphine; protonitazene ~2 times fentanyl and ~200 times morphine. The metabolite N-desethyl isotonitazene is more potent than its parent and can cause longer-lasting respiratory depression.
  • In Tennessee, 52 nitazene-involved fatal overdoses occurred from 2019 to 2021, rising fourfold from 10 cases in 2020 to 42 in 2021, with metonitazene accounting for 85.7% of these deaths in 2021. In Europe, 21 of 27 EU Member States plus Norway reported nitazenes since 2019; 22 nitazenes have been detected in Europe, and nitazene powder seized in 2023 tripled to 10 kg compared with 2022.
  • Traditional immunoassays and fentanyl test strips are largely ineffective for nitazenes; detection often requires liquid chromatography–mass spectrometry because concentrations in biological samples are typically sub-ng/mL or sub-pmol/mL. Naloxone remains effective, but higher, repeated, or continuous doses may be needed due to high potency, slow MOR dissociation, and prolonged active metabolites.

Methods

  • Perspective paper that synthesises published literature, toxicology reports, surveillance data, and regulatory sources; no primary experimental data are presented.
  • Covers global epidemiology, pharmacology and toxicity, analytical challenges, and strategic responses, including detection, clinical management, harm reduction, and policy.
  • No systematic review protocol, meta-analysis, or primary sample collection is described.

Limitations

  • The paper does not present a formal limitations section; it states that information on nitazene pharmacology, toxicology, and harms remains limited, and that studies on monointoxications, human pharmacokinetics, and non-rodent species are lacking.
  • Evident from the text: as a perspective/narrative review, evidence selection is not systematic, and many quantitative claims rely on cited reports and surveillance systems that may underestimate nitazene-related deaths and intoxications.
  • The paper notes that detection is constrained by inaccessible high-resolution instruments, limited reference standards, and underreporting, especially in low-income countries.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/molecules30193890

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Chemical structure of fentanyl, morphine and etonitazene. Marvin was used for drawing the chemical structures: Marvin 17.21.0, Chemaxon (https://www.chemaxon.com).
Figure 1 Chemical structure of fentanyl, morphine and etonitazene. Marvin was used for drawing the chemical structures: Marvin 17.21.0, Chemaxon (https://www.chemaxon.com).CC BY · PubMed Central
Figure 2 Nitazene core structure and 12 analogues under the UNODC International Drug Control Conventions [17]. Marvin was used for drawing the chemical structures: Marvin 17.21.0, Chemaxon (https://www.chemaxon.com).
Figure 2 Nitazene core structure and 12 analogues under the UNODC International Drug Control Conventions [17]. Marvin was used for drawing the chemical structures: Marvin 17.21.0, Chemaxon (https://www.chemaxon.com).CC BY · PubMed Central
Figure 3 Top new opioids seized (a) by number of seizures (749 seizures) and (b) by quantity seized (16.6 kg seized) reported to the EU Early Warning System, 2022. Adapted from EUDA [26].
Figure 3 Top new opioids seized (a) by number of seizures (749 seizures) and (b) by quantity seized (16.6 kg seized) reported to the EU Early Warning System, 2022. Adapted from EUDA [26].CC BY · PubMed Central

Verification

Claims the paper makes

35 Valid · 9 Not valid · 19 Not checked · 15 Own results and interpretations

24 more claims · 12 with their cited sources checked

Create a free account to see all 78 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 41
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 64 references

Cited by

See all 21

Metadata

Authors
Pereira, J. R. P., Quintas, A., & Neng, N. R.
Affiliations
  • University of Lisbon (PT)
  • Escola Superior de Saúde Egas Moniz (PT)
Corresponding author
Neng, Nuno R.
Venue
Molecules
Publisher
MDPI AG
Published
2025-09-26
Volume
30
Issue
19
Pages
3890
ISSN
1420-3049 (ISSN-L)
OpenAlex
W4414546090
Cited by
21
References
64
Citations by year
2026: 21
FWCI
3.65
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
FCT (UIDB/00100/2020, UIDP/00100/2020, LA/P/0056/2020, 10.54499/UIDB/04585/2020)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
Keywords
nitazenes, synthetic opioids, etonitazene, isotonitazene, opioid overdose, respiratory depression, drug adulteration, counterfeit drugs, drug detection, clinical management, drug regulation, pharmacovigilance
MeSH terms
Analgesics, Opioid, Animals, Humans, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nitazenes: The Emergence of a Potent Synthetic Opioid Threat. https://app.cochat.ai/papers/10.3390/molecules30193890
The paper
Pereira, J. R. P., Quintas, A., & Neng, N. R. (2025). Nitazenes: The Emergence of a Potent Synthetic Opioid Threat. Molecules. https://doi.org/10.3390/molecules30193890

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.